Trial Profile
A Phase II Combination Study of MT-3724 and Chemotherapy in Earlier Lines of Diffuse Large B-Cell lymphoma (DLBCL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2020
Price :
$35
*
At a glance
- Drugs MT 3724 (Primary) ; Antineoplastics
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Molecular Templates
- 04 Nov 2020 According to a Molecular Templates media release, the FDA has placed MT-3724 clinical studies on partial clinical hold pending further review of a treatment-related fatality in a single subject in the Phase 2 monotherapy study.
- 04 Nov 2020 Status changed from planning to withdrawn prior to enrolment, according to a Molecular Templates media release.
- 02 Dec 2018 New trial record